Quantum-Si Inc

Listed Company

QSICIK 0001816431NasdaqNon-AcceleratedSmaller ReportingMeasuring & Controlling Devices, NecDelawareFY ends Dec 31

Period

FY 2025

Revenue

$2.44M

Net Income

$-101.30M

Total Assets

$245.61M

Equity

$220.23M

Shares Out

—

Op. Cash Flow

$-94.72M

Business

Quantum-Si Inc is a life sciences company developing and commercializing single-molecule proteomics research tools centered on Next-Generation Protein Sequencing (NGPS). It offers instrumentation (Platinum and Platinum Pro), consumable kits for library preparation and sequencing, and cloud/on-instrument automated data analysis software. The business operates as a platform provider with product lines for instruments, consumables, and software while pursuing a next-generation Proteus platform and partnerships for expanded applications. Quantum-Si sells through a direct U.S. sales force, a mix of direct and distributor channels in Europe, and international distribution partners including a North American distributor.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	2	3	1	0	0
Cost of revenue	1	1	594,000	0	0
Gross profit	1	2	488,000	0	0
Research and development	54	60	67	72	47
Selling, general and administrative	45	51	45	42	50
Lease termination expense, net	14	0	0	—	—
Legal settlement expense, net of insurance proceeds	5	0	0	—	—
Total operating expenses	117	110	112	124	97
Loss from operations	−116	−109	−111	−124	−97
Dividend income	697,000	2	9	5	3
Interest income	9	10	459,000	—	—
Unrealized gain on trading securities	0	0	11	−16	—
Realized loss on trading securities	0	0	−5	−4	—
Change in fair value of warrant liabilities	4	−4	−300,000	6	4
Other income (expense), net	955,000	−19,000	366,000	458,000	19,000
Loss before provision for income taxes	−101	−101	−96	−132	−95
Provision for income taxes	−58,000	−56,000	0	0	0
Net loss	−101	−101	−96	−132	−95
Basic net loss per share (in dollars per share)	−0.51	−0.71	−0.68	−0.95	−1.19
Diluted net loss per share (in dollars per share)	−0.51	−0.71	−0.68	−0.95	−1.19
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic (in shares)	198	143	141	139	80
Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted (in shares)	198	143	141	139	80
Net unrealized (loss) gain on marketable securities, net of tax	−63,000	70,000	0	0	—
Foreign currency translation adjustment	12,000	−25,000	0	0	—
Total other comprehensive (loss) gain, net of tax	−51,000	45,000	0	0	—
Comprehensive loss	−101	−101	−96	−132	−95

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	22	49	134	84	36
Marketable securities, current	141	160	—	—	—
Accounts receivable, net of allowance of $270 and $124, respectively	561,000	1	368,000	0	—
Legal settlement insurance receivable	5	0	—	—	—
Inventory	3	4	4	0	—
Prepaid expenses and other current assets	5	3	4	7	6
Total current assets	176	218	266	358	477
Marketable securities, non-current	53	0	—	—	—
Property and equipment, net	13	16	16	17	9
Operating lease right-of-use assets	3	13	14	16	7
Other assets	234,000	808,000	695,000	697,000	690,000
Total assets	246	248	298	391	503
Accounts payable	2	2	2	4	3
Accrued payroll and payroll-related costs	6	5	5	6	—
Accrued contracted services	3	2	2	4	—
Accrued legal settlement liability	8	0	—	—	—
Accrued expenses and other current liabilities	2	5	2	1	7
Warrant liabilities, current	794,000	0	—	—	—
Current portion of operating lease liabilities	2	4	2	1	859,000
Total current liabilities	23	18	12	16	12
Warrant liabilities, non-current	0	5	1	1	7
Operating lease liabilities	2	9	14	16	7
Other long-term liabilities	34,000	19,000	11,000	0	206,000
Total liabilities	25	32	27	33	26
Commitments and contingencies (Note 17)	—	—	—	—	—
Additional paid-in capital	918	812	767	758	744
Accumulated other comprehensive (loss) income	−6,000	45,000	0	—	—
Accumulated deficit	−698	−597	−496	−400	−267
Total stockholders equity	220	215	272	359	477
Total liabilities and stockholders equity	246	248	298	391	503

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	4	5	4	3	1
Allowance for credit losses	146,000	124,000	0	0	—
Non-cash lease expense	2	2	1	1	415,000
Loss on lease termination	2	0	0	—	—
Write-off of construction on process due to lease termination	1	0	0	—	—
Accretion on marketable securities	−8	−8	0	0	—
Loss on disposal of fixed assets	31,000	425,000	136,000	91,000	70,000
Write-down of inventory	2	−3	−3	0	—
Change in fair value of warrant liabilities	−4	4	278,000	−6	−4
Change in fair value of contingent consideration	0	0	−400,000	176,000	36,000
Stock-based compensation	11	9	9	11	25
Other	−1,000	22,000	0	0	—
Accounts receivable, net	626,000	−1	−368,000	0	0
Legal settlement insurance receivable	−5	0	0	—	—
Inventory	−2	4	286,000	0	0
Prepaid expenses and other current assets	−2	486,000	2	−1	−5
Operating lease right-of-use assets	0	0	−83,000	−10	−7
Other assets	3,000	−113,000	2,000	−7,000	−690,000
Accounts payable	−338,000	390,000	−1	721,000	709,000
Accrued expenses and other current liabilities	−1	4	−2	4	4
Accrued legal settlement liability	8	0	0	—	—
Other long-term liabilities	14,000	7,000	7,000	0	0
Operating lease liabilities	−3	−3	−2	9	8
Net cash used in operating activities	−95	−88	−94	−91	−67
Purchases of property and equipment	−3	−5	−5	−11	−6
Internally developed software - capitalized costs	0	−59,000	−763,000	0	0
Purchases of marketable securities	−405	−369	−124	−834,000	−441
Sales and maturities of marketable securities	379	341	273	149	0
Net cash (used in) provided by investing activities	−28	−33	143	137	−451
Proceeds from exercise of stock options	2	1	357,000	3	6
Proceeds from vesting of restricted stock	1,000	1,000	0	0	—
Proceeds from issuance of common stock from direct equity offerings and the exercise of public and pre-funded warrants, net of fees and issuance costs	94	0	0	—	—
Proceeds from issuance of common stock from at-the-market offering, net of commissions and issuance costs	0	35	0	0	—
Deferred offering costs	0	0	−208,000	0	−4,000
Refund of issuance costs	0	14,000	0	0	—
Net cash provided by financing activities	95	36	149,000	2	517
Effect of exchange rate changes on cash and cash equivalents	12,000	−25,000	0	0	—
Net (decrease) increase in cash and cash equivalents	−28	−85	50	49	—
Cash received from exchange of research and development tax credits	2	0	2	0	173,000
Cash paid for taxes	24,000	0	0	—	—
Property and equipment purchased but not paid	217,000	337,000	302,000	1	1
Transfers from inventory to property and equipment	1	0	0	—	—
Deferred offering costs payable	0	553,000	105,000	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro